HCW Biologics Advances Immunotherapy with TGF-β/IL-15 Fusion Moiety
Event summary
- HCW Biologics identified a TGF-β trap and IL-15 fusion moiety that promotes expansion of CD8+ T cells and NK cells, showing clinical benefit and tolerability in cancer patients.
- The moiety demonstrated activity against HIV-1 and bronchopulmonary dysplasia in animal models.
- HCW Biologics incorporated the moiety into its second-generation TCE and ICI programs, with lead candidates HCW11-018b and HCW11-040 at IND-enabling stage.
- Clinical studies for both candidates are planned to initiate in 2027.
The big picture
HCW Biologics' development of the TGF-β/IL-15 fusion moiety represents a strategic shift in immunotherapy, aiming to enhance anti-tumor activity and address senescence-associated dysplasia. The incorporation of this moiety into second-generation fusion immunotherapeutics positions the company to challenge traditional approaches in the immunotherapy field, particularly in treating solid tumors and chronic inflammatory diseases. The planned clinical studies in 2027 will be critical in validating the moiety's potential and differentiating HCW Biologics' offerings in a competitive market.
What we're watching
- Clinical Efficacy
- Whether the TGF-β/IL-15 moiety can sustain superior immune-cell activation and tumor infiltration in human trials.
- Regulatory Approval
- The pace at which HCW Biologics can navigate IND-enabling stages and initiate clinical studies for HCW11-018b and HCW11-040.
- Market Differentiation
- How HCW Biologics' multi-valent immunotherapeutics will compete against established immune checkpoint inhibitors like Keytruda®.
Related topics